Every 10-Q that Fate Therapeutics, Inc. (FATE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FATE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FATE filings page.
Fate Therapeutics, Inc. reported a net loss of $30.2 million for the quarter and $61.4 million for the six months ended June 30, 2026, modestly improved from 2025 as operating expenses declined. Collaboration revenue was $3.4 million for the first half, primarily from its Ono Pharmaceutical arrangement.
Cash, cash equivalents and short-term investments totaled $153.8 million at June 30, 2026, and management expects this to fund operations for at least 12 months. The company used $54.3 million of cash in operating activities in the first half and had total assets of $260.1 million, including significant lease right-of-use assets.
Fate remains a clinical-stage cell therapy company focused on iPSC-derived immunotherapies, with no product sales and an accumulated deficit of $1.6 billion. It continues to fund development through collaborations, notably with Ono, and through CIRM awards for FT819 and FT836, which are currently accounted for as liabilities.
Fate Therapeutics reported a Q1 2026 net loss of $31.2 million, improving from a $37.6 million loss a year earlier, as it continued investing in its off-the-shelf iPSC-derived cell therapy pipeline. Collaboration revenue was $1.3 million compared with $1.6 million in Q1 2025, all from research and preclinical services under its Ono partnership.
Research and development expenses were $24.7 million versus $29.1 million, and general and administrative expenses were $9.6 million versus $13.8 million, reflecting ongoing cost reductions. Cash, cash equivalents and short‑term investments totaled $174.8 million as of March 31, 2026, and management believes this will fund operations for at least twelve months. The company remains a clinical‑stage biopharmaceutical business with an accumulated deficit of about $1.6 billion and no product sales to date.
Fate Therapeutics reported Q3 2025 results. Collaboration revenue was $1.7 million, down from $3.1 million a year ago, reflecting lower recognition under its Ono collaboration. Operating expenses fell to $36.5 million from $55.5 million as R&D and G&A were reduced. Net loss narrowed to $32.3 million from $47.7 million, and loss per share improved to $0.27 from $0.40.
Liquidity and cash flows: Cash and cash equivalents were $40.6 million, with short-term investments of $174.8 million and long-term investments of $10.3 million. Total current assets were $221.3 million. Net cash used in operations for the nine months was $82.8 million, partially offset by $83.5 million net inflows from investment activity and $3.8 million from a CIRM award.
Operational updates: The company implemented an August 2025 restructuring, recording $1.1 million in severance and related costs. It recognized $1.7 million in Q3 revenue and $5.3 million year-to-date under the Ono arrangement, with committed funding through June 2026. As of November 6, 2025, 115,352,289 common shares were outstanding.